Pleros Christos, Adamidis Konstantinos, Kantartzi Konstantia, Griveas Ioannis, Baltsavia Ismini, Moustakas Aristides, Kalliaropoulos Antonios, Fraggedaki Evaggelia, Petra Christina, Damianakis Nikolaos, Mentis Andreas, Drosataki Eleni, Petrakis Ioannis, Passadakis Ploumis, Panagopoulos Periklis, Stylianou Kostas, Panagoutsos Stylianos
Nephrology Department, University Hospital of Heraklion, 71500 Heraklion, Greece.
Dialysis Unit Bionephros, 18345 Athens, Greece.
J Clin Med. 2023 Sep 26;12(19):6205. doi: 10.3390/jcm12196205.
(1) Background: Chronic inflammation and suboptimal immune responses to vaccinations are considered to be aspects of immune dysregulation in patients that are undergoing dialysis. The present study aimed to evaluate immune responses in hemodialysis (HD) and online hemodiafiltration (OL-HDF) patients to a seasonal inactivated quadrivalent influenza vaccine (IQIV). (2) Methods: We enrolled 172 chronic dialysis patients (87 on HD and 85 on OL-HDF) and 18 control subjects without chronic kidney disease in a prospective, cross-sectional cohort study. Participants were vaccinated with a seasonal IQIV, and antibody titers using the hemagglutination inhibition (HI) assay were determined before vaccination (month 0) and 1, 3, and 6 months thereafter. Demographics and inflammatory markers (CRP, IL-6, IL-1β) were recorded at month 0. The primary endpoints were the rates of seroresponse (SR), defined as a four-fold increase in the HI titer, and seroprotection (SP), defined as HI titer ≥ 1/40 throughout the study period. Statistical analyses were conducted in R (version 3.6.3) statistical software. The differences between groups were analyzed using chi-square and -test analyses for dichotomous and continuous variables, respectively. To identify independent determinants of SR and SP, generalized linear models were built with response or protection per virus strain as the dependent variable and group, age, sex, time (month 0, 1, 3, 6), diabetes, IL-6, dialysis vintage, HD access, and HDF volume as independent explanatory variables. (3) Results: SR and SP rates were similar between control subjects, and dialysis patients were not affected by dialysis modality. SP rates were high (> 70%) at the beginning of the study and practically reached 100% after vaccination in all study groups. These results applied to all four virus strains that were included in the IQIV. IL-6 levels significantly differed between study groups, with HD patients displaying the highest values, but this did not affect SP rates. (4) Conclusions: Dialysis patients respond to influenza immunization adequately and similarly to the general population. Thus, annual vaccination policies should be encouraged in dialysis units. OL-HDF reduces chronic inflammation; however, this has no impact on SR rates.
(1) 背景:慢性炎症以及对疫苗接种的免疫反应欠佳被认为是正在接受透析的患者免疫失调的表现。本研究旨在评估血液透析(HD)和在线血液透析滤过(OL-HDF)患者对季节性四价流感灭活疫苗(IQIV)的免疫反应。(2) 方法:我们纳入了172例慢性透析患者(87例接受HD,85例接受OL-HDF)以及18例无慢性肾脏病的对照受试者,进行一项前瞻性横断面队列研究。参与者接种季节性IQIV疫苗,并在接种前(第0个月)以及之后的第1、3和6个月使用血凝抑制(HI)试验测定抗体滴度。在第0个月记录人口统计学和炎症标志物(CRP、IL-6、IL-1β)。主要终点是血清反应率(SR),定义为HI滴度增加四倍,以及血清保护率(SP),定义为在整个研究期间HI滴度≥1/40。在R(版本3.6.3)统计软件中进行统计分析。分别使用卡方检验和t检验分析二分变量和连续变量的组间差异。为了确定SR和SP的独立决定因素,构建广义线性模型,将每种病毒株的反应或保护作为因变量,将组、年龄、性别、时间(第0、1、3、6个月)、糖尿病、IL-6、透析龄、HD通路和HDF容量作为独立解释变量。(3) 结果:对照受试者之间的SR和SP率相似,透析患者不受透析方式影响。在研究开始时SP率较高(>70%),在所有研究组中接种疫苗后实际上达到100%。这些结果适用于IQIV中包含的所有四种病毒株。研究组之间IL-6水平存在显著差异,HD患者的值最高,但这并不影响SP率。(4) 结论:透析患者对流感免疫的反应与普通人群充分且相似。因此,应鼓励在透析单位实施年度疫苗接种政策。OL-HDF可减轻慢性炎症;然而,这对SR率没有影响。